.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Medtronic
QuintilesIMS
Mallinckrodt
Johnson and Johnson
Teva
Chinese Patent Office
Express Scripts
Harvard Business School
Boehringer Ingelheim

Generated: June 28, 2017

DrugPatentWatch Database Preview

REVATIO Drug Profile

« Back to Dashboard

What is the patent landscape for Revatio, and what generic Revatio alternatives are available?

Revatio is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in REVATIO is sildenafil citrate. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

Summary for Tradename: REVATIO

Patents:0
Applicants:1
NDAs:3
Suppliers / Packagers: see list5
Bulk Api Vendors: see list112
Clinical Trials: see list47
Patent Applications: see list3,068
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:REVATIO at DailyMed

Pharmacology for Tradename: REVATIO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
REVATIO
sildenafil citrate
FOR SUSPENSION;ORAL203109-001Aug 30, 2012RXYesYes► Subscribe► Subscribe
Pfizer
REVATIO
sildenafil citrate
TABLET;ORAL021845-001Jun 3, 2005ABRXYesYes► Subscribe► Subscribe
Pfizer
REVATIO
sildenafil citrate
SOLUTION;INTRAVENOUS022473-001Nov 18, 2009APRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: REVATIO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
REVATIO
sildenafil citrate
TABLET;ORAL021845-001Jun 3, 20055,250,534*PED► Subscribe
Pfizer
REVATIO
sildenafil citrate
SOLUTION;INTRAVENOUS022473-001Nov 18, 20095,250,534*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Accenture
Teva
Moodys
Argus Health
Chinese Patent Office
Healthtrust
UBS
Cipla
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot